A trial of a new combination of treatment for newly diagnosed high risk myeloma and plasma cell leukaemia (MUK 9 b OPTIMUM)

This trial is looking at a new combination of drugs before a stem cell transplant and long term treatment for high risk myeloma and plasma cell leukaemia.

Myeloma is a type of blood cancer that starts in the bone marrow. Plasma cell leukaemia is a very rare type of blood cancer. It is similar to myeloma as it affects the plasma cells (PCL) in the blood and bone marrow. PCL and high risk myeloma are treated in the same way. So, when we refer to myeloma in the summary, we mean both.